ALMS logo

ALMS
Alumis Inc.

1,108
Mkt Cap
$3.7B
Volume
2.05M
52W High
$30.60
52W Low
$2.76
PE Ratio
-7.70
ALMS Fundamentals
Price
$29.69
Prev Close
$29.98
Open
$29.72
50D MA
$21.58
Beta
0.81
Avg. Volume
6.43M
EPS (Annual)
-$5.41
P/B
8.05
Rev/Employee
$0.00
$170.10
Loading...
Loading...
News
all
press releases
Alumis Inc. (NASDAQ:ALMS) Given Average Rating of "Moderate Buy" by Brokerages
Shares of Alumis Inc. (NASDAQ:ALMS - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the twelve brokerages that are currently covering the company, Marketbeat Ratings...
MarketBeat·22h ago
News Placeholder
More News
News Placeholder
Alumis Shares Phase 3 Psoriasis Details, Targets 2H NDA Filing at Oppenheimer Healthcare Conference
Executives from Alumis (NASDAQ:ALMS) outlined upcoming regulatory milestones and provided additional context around recently announced Phase 3 psoriasis results for envudeucitinib during a fireside...
MarketBeat·3d ago
News Placeholder
Stifel Nicolaus Initiates Coverage on Alumis (NASDAQ:ALMS)
Stifel Nicolaus assumed coverage on Alumis in a research note on Wednesday. They set a "buy" rating and a $44.00 price objective on the stock...
MarketBeat·5d ago
News Placeholder
Alumis (NASDAQ:ALMS) Sets New 52-Week High - Still a Buy?
Alumis (NASDAQ:ALMS) Hits New 12-Month High - Here's What Happened...
MarketBeat·10d ago
News Placeholder
Credit Industriel ET Commercial Sells 140,000 Shares of Alumis Inc. $ALMS
Credit Industriel ET Commercial lessened its holdings in shares of Alumis Inc. (NASDAQ:ALMS - Free Report) by 36.2% in the third quarter, according to the company in its most recent disclosure with...
MarketBeat·14d ago
News Placeholder
Alumis (NASDAQ:ALMS) Shares Up 7.2% - Still a Buy?
Alumis (NASDAQ:ALMS) Trading 7.2% Higher - Still a Buy...
MarketBeat·17d ago
News Placeholder
Alumis Highlights Phase III Psoriasis Wins, NDA Timing, and Lupus Catalyst at Guggenheim Summit
Executives from Alumis (NASDAQ:ALMS) outlined recent clinical results, upcoming regulatory milestones, and pipeline priorities during a discussion at the Guggenheim Emerging Outlook Biotech Summit...
MarketBeat·17d ago
News Placeholder
Alumis Inc. (NASDAQ:ALMS) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Shares of Alumis Inc. (NASDAQ:ALMS - Get Free Report) have been assigned an average rating of "Moderate Buy" from the eleven ratings firms that are covering the stock, Marketbeat reports. One...
MarketBeat·26d ago
News Placeholder
Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter.
Key PointsBML Capital Management sold 1,210,415 shares of Alumis in the fourth quarter...
Nasdaq News: Markets·27d ago
News Placeholder
Alumis Inc. (NASDAQ:ALMS) Short Interest Up 93.1% in January
Alumis Inc. (NASDAQ:ALMS - Get Free Report) saw a significant growth in short interest during the month of January. As of January 15th, there was short interest totaling 8,672,088 shares, a growth of...
MarketBeat·1mo ago
<
1
2
...
>

Latest ALMS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.